Cidara Therapeutics, Inc

(NASDAQ:CDTX)

Latest On Cidara Therapeutics, Inc (CDTX):

Date/Time Type Description Signal Details
2023-05-21 14:04 ESTNewsBuy Cidara Therapeutics For Data Readout And European FootholdN/A
2023-05-11 17:50 ESTNewsCidara Therapeutics GAAP EPS of $0.03 beats by $0.07, revenue of $25.99M beats by $7.31MN/A
2023-05-03 22:01 ESTNewsCidara Therapeutics: Promising Developments And A Speculative 'Buy' Recommendation (Rating Upgrade)N/A
2023-04-24 16:32 ESTNewsCidara earns $20M milestone payment on FDA nod for antifungalN/A
2023-03-23 16:47 ESTNewsCidara stock dips amid FDA approval of antifungal drug RezzayoN/A
2023-03-23 16:47 ESTNewsCidara Therapeutics GAAP EPS of -$0.19 misses by $0.04, revenue of $10.22M misses by $0.35MN/A
2023-03-23 16:46 ESTNewsCidara off 27% despite FDA nod amid selloff in antifungal spaceN/A
2023-03-23 00:46 ESTNewsDeadly fungal infection sweeps across U.S.N/A
2023-03-22 09:08 ESTNewsCidara extends gains ahead of FDA decision on antifungal therapyN/A
2023-03-18 12:54 ESTNewsStocks To Watch: All Eyes On The Federal ReserveN/A
2023-03-07 17:23 ESTNewsCDTX, PTGX and TAST among premarket gainersN/A
2023-03-03 19:34 ESTNewsCidara stock slumps ~15% on common stock, preferred shares offeringsN/A
2023-03-03 19:34 ESTNewsCidara secures capital raise of $17M; stock down 18%N/A
2023-03-02 00:02 ESTNewsCidara stock pops as CD388 helps cut influenza risk in phase 2a trialN/A
2023-03-02 00:01 ESTNewsCidara Therapeutics adds 31% on mid-stage data of flu prophylactic drugN/A
2023-02-28 02:47 ESTNewsCidara Therapeutics Sheds Skin, Shifts To ImmunotherapyN/A
2023-02-14 20:23 ESTNewsCidara Therapeutics regains compliance with Nasdaq's minimum bid price ruleN/A
2023-01-30 12:22 ESTNewsCidara Therapeutics: FDA Approval Dead AheadN/A
2023-01-25 14:54 ESTNewsCidara jumps 17% after FDA AdCom nod for antifungal drugN/A
2023-01-20 16:18 ESTNewsCidara on watch as FDA docs are released ahead of AdCom on antifungal drugN/A
2022-11-16 09:23 ESTNewsCidara Therapeutics Could Soar On Rezafungin ApprovalN/A
2022-11-04 00:38 ESTNewsCidara Therapeutics GAAP EPS of $0.17 beats by $0.10, revenue of $40.74M beats by $18.06MN/A
2022-10-04 14:17 ESTNewsCidara spikes on $11M milestone payment from partner MundipharmaN/A
2022-10-04 14:17 ESTNewsCidara Therapeutics receives $11.1M milestone payment from MundipharmaN/A
2022-09-14 02:18 ESTNewsCidara begins dosing of antiviral CD388 in trial for preventing influenzaN/A
2022-08-09 20:45 ESTNewsCidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01MN/A
2022-07-27 17:14 ESTNewsCidara stock soars 29% on FDA approval filing for rezafungin, sale of US rights for drug for $30M upfrontN/A
2022-07-02 13:21 ESTNewsStocks To Watch: Spotlight On Airlines, Dividend Plays And MinionsN/A
2022-05-12 14:44 ESTNewsH.C. Wainwright analyst lowers price target on Cidara TherapeuticsN/A
2022-05-11 20:50 ESTNewsCidara Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $7.11M beats by $2.4MN/A
2022-04-01 20:33 ESTNewsCidara gains on dosing milestone in early-stage trial for flu candidateN/A
2022-04-01 04:02 ESTNewsCidara doses first group in phase 1 trial of CD388 for treating/preventing influenzaN/A
2022-03-08 10:50 ESTNewsCidara Therapeutics GAAP EPS of -$0.26, revenue of $7.2MN/A
2022-03-03 09:08 ESTNewsCidara/Mundipharma rezafungin gets promising innovative medicine status in UKN/A
2022-02-15 01:56 ESTNewsCidara announces FDA acceptance of its request to study the flu candidateN/A
2021-12-15 07:37 ESTNewsCidara decline continues as shares decline 30% on late-stage antifungal dataN/A
2021-12-14 11:40 ESTNewsCidara drops 5% despite 'positive' Phase 3 rezafungin data in candidemia/invasive candidiasisN/A
2021-11-11 03:06 ESTNewsCidara Therapeutics EPS misses by $0.02, beats on revenueN/A
2021-10-09 00:36 ESTNewsCidara Therapeutics slumps 9% amid pricing of common/preferred stock offeringsN/A
2021-10-08 04:54 ESTNewsCidara Therapeutics plunges on launching stock and preferred stock offeringsN/A
2021-09-21 14:01 ESTNewsCidara Therapeutics (CDTX) Investor Presentation - SlideshowN/A
2021-08-17 10:34 ESTNewsCidara Therapeutics and Mundipharma complete enrollment in late-stage rezafungin trialN/A
2021-08-13 10:37 ESTNewsCidara Therapeutics EPS beats by $0.41, beats on revenueN/A
2021-07-20 23:29 ESTNewsCidara Therapeutics' chief financial officer James Levine resignsN/A
2021-07-20 23:23 ESTNewsCidara Therapeutics posts new analyses from multiple rezafungin studies at ECCMIDN/A
2021-07-20 23:16 ESTNewsCidara Therapeutics: Rezafungin Data Could Bring ValueN/A
2021-04-06 00:27 ESTNewsTSLA, NVTA, CHPT and NNOX among premarket gainersN/A
2021-04-06 00:27 ESTNewsCidara shares gain 15% on antiviral conjugates development deal with JanssenN/A
2021-03-27 18:56 ESTNewsChecking Back In On Cidara TherapeuticsN/A
2021-03-10 15:16 ESTAnalyst RatingThe Analyst Target Price has increased from $6.4 to $6.83.Buy

About Cidara Therapeutics, Inc (CDTX):

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

CDTX Quotes by TradingView

See Advanced Chart

General

  • Name Cidara Therapeutics, Inc
  • Symbol CDTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2015-04-15
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cidara.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 7.89
  • Price/Book (Most Recent Quarter) 10.27
  • Enterprise Value Revenue 6.8
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.61
  • Next Year EPS Estimate -$1.44
  • Next Quarter EPS Estimate -$0.31
  • Operating Margin -595%
  • Return on Assets -69%
  • Return on Equity -297%
  • Revenue 12.07 million
  • Earnings Per Share -$2.14
  • Revenue Per Share $0.29
  • Gross Profit -55950000
  • Quarterly Earnings Growth 105.5%
View More

Highlights

  • Market Capitalization 115.78 million
  • EBITDA -61577000
  • PE Ratio -1.65
  • Analyst Target Price $6.83
  • Book Value Per Share $0.24
View More

Share Statistics

  • Shares Outstanding 48.04 million
  • Shares Float 35.28 million
  • % Held by Insiders 1754%
  • % Held by Institutions 65.31%
  • Shares Short 1.6 million
  • Shares Short Prior Month 1.59 million
  • Short Ratio 1.06
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.47
  • 52 Week High $4.34
  • 52 Week Low $1.82
  • 50 Day Moving Average 2.54
  • 200 Day Moving Average 2.58
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cidara Therapeutics, Inc (CDTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cidara Therapeutics, Inc (CDTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.48-$0.24-100%
2020-09-302020-11-05$N/A-$0.41-$0.40-1.61%
2020-06-302020-08-13$N/A-$0.45-$0.31-44.79%
2020-03-312020-05-13$2.53 million-$0.46-$0.34-35.33%
2019-12-312020-03-04$1.82 million-$0.42-$0.433%
2019-09-302019-11-08$19.1 million$0.08-$0.26131.1%
2019-06-302019-08-08$N/A-$0.49-$0.5713.31%
2019-03-312019-05-09$N/A-$0.60-$0.600.7%
2018-12-312019-02-28$N/A-$0.44-$0.5924.99%
2018-09-302018-11-08$N/A-$0.49-$0.6018.67%
2018-06-302018-08-08$N/A-$1.13-$0.67-69.49%
2018-03-312018-05-10$N/A-$0.80-$0.64-24.22%
2017-12-312018-02-27$N/A-$0.69-$0.758.17%
2017-09-302017-11-08$N/A-$0.73-$0.9422.69%
2017-06-302017-08-09$N/A-$0.99-$0.87-13.98%
2017-03-312017-05-10$N/A-$0.80-$0.888.95%
2016-12-312017-03-15$N/A-$0.88-$0.78-13.3%
2016-09-302016-11-10$N/A-$0.88-$0.880.45%
2016-06-302016-08-11$N/A-$0.85-$0.77-11.11%
2016-03-312016-05-12$N/A-$0.71-$0.733.18%
2015-12-312016-03-18$N/A-$0.72-$0.70-2.27%
2015-09-302015-11-16$N/A-$0.67-$0.57-17.54%
2015-06-302015-08-11$N/A-$0.59-$0.57-3.51%
2015-03-312015-04-15$N/A-$5.92-$0.70-745.71%

Cidara Therapeutics, Inc (CDTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cidara Therapeutics, Inc (CDTX) Chart:

Cidara Therapeutics, Inc (CDTX) News:

Below you will find a list of latest news for Cidara Therapeutics, Inc (CDTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cidara Therapeutics, Inc (CDTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.05CALL1 139471.68FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.51.7PUT0 30TRUE00
2024-05-1750PUT0 00TRUE00
2024-05-177.50PUT0 00TRUE00
2024-06-212.50.05CALL110 1738296.45FALSE0.020.67
2024-06-2150.05CALL0 10FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 00TRUE00
2024-06-2150PUT0 00TRUE00
2024-06-217.50PUT0 00TRUE00
2024-09-202.50.1CALL0 1524207.36FALSE00
2024-09-2050.05CALL0 6550FALSE00
2024-09-207.50CALL0 00FALSE00
2024-09-202.52PUT0 10895.53TRUE00
2024-09-2050PUT0 00TRUE00
2024-09-207.50PUT0 00TRUE00
2024-12-202.50CALL0 00FALSE00
2024-12-2050CALL0 00FALSE00
2024-12-207.50CALL0 00FALSE00
2024-12-202.50PUT0 00TRUE00
2024-12-2050PUT0 00TRUE00
2024-12-207.50PUT0 00TRUE00

Latest CDTX Trades:

Date Shares Price
Jun 13, 2022 7:56 PM EST43$0.4997
Jun 13, 2022 7:56 PM EST43$0.4997
Jun 13, 2022 7:59 PM EST200$0.5025
Jun 13, 2022 7:59 PM EST100$0.5025
Jun 13, 2022 7:59 PM EST100$0.5025

Cidara Therapeutics, Inc (CDTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120039025/0001209191-20-039025-index.htm
2019-11-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1610618/000000000019015876/0000000000-19-015876-index.htm
2019-12-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1610618/000000000019016205/0000000000-19-016205-index.htm
2020-06-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1610618/000000000020005122/0000000000-20-005122-index.htm
2018-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000031506618002315/0000315066-18-002315-index.htm
2019-09-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000089383819000020/0000893838-19-000020-index.htm
2018-12-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000092189518003393/0000921895-18-003393-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000092189520000528/0000921895-20-000528-index.htm
2020-02-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000093583620000166/0000935836-20-000166-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000095014219000199/0000950142-19-000199-index.htm
2019-09-038-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000114036119015933/0001140361-19-015933-index.htm
2019-11-20SC TO-ITender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/1610618/000114036119020978/0001140361-19-020978-index.htm
2019-12-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1610618/000114036119021903/0001140361-19-021903-index.htm
2019-12-04SC TO-I/ATender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/1610618/000114036119021904/0001140361-19-021904-index.htm
2019-12-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1610618/000114036119022238/0001140361-19-022238-index.htm
2019-12-20SC TO-I/ATender offer statement by Issuerhttps://www.sec.gov/Archives/edgar/data/1610618/000114036119022987/0001140361-19-022987-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000114036120000607/0001140361-20-000607-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000114036120001203/0001140361-20-001203-index.htm
2020-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1610618/000114036120001205/0001140361-20-001205-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000114036120002603/0001140361-20-002603-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000114036120002977/0001140361-20-002977-index.htm
2020-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1610618/000114036120013123/0001140361-20-013123-index.htm
2020-06-11S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1610618/000114036120013613/0001140361-20-013613-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1610618/000114036120013614/0001140361-20-013614-index.htm
2020-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1610618/000114036120013693/0001140361-20-013693-index.htm
2020-06-17424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1610618/000114036120014052/0001140361-20-014052-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000114036120014775/0001140361-20-014775-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000114036120014777/0001140361-20-014777-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000114036120014780/0001140361-20-014780-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000114036120014783/0001140361-20-014783-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000114036120014785/0001140361-20-014785-index.htm
2018-11-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1610618/000119312518322534/0001193125-18-322534-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000119312518322646/0001193125-18-322646-index.htm
2018-11-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1610618/000119312518325665/0001193125-18-325665-index.htm
2018-11-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1610618/000119312518328972/0001193125-18-328972-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000119312519037834/0001193125-19-037834-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000119312519037869/0001193125-19-037869-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000119312519039514/0001193125-19-039514-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000119312519204788/0001193125-19-204788-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000119312520037526/0001193125-20-037526-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000119312520037795/0001193125-20-037795-index.htm
2018-08-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118048682/0001209191-18-048682-index.htm
2018-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118050649/0001209191-18-050649-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118050651/0001209191-18-050651-index.htm
2018-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118051580/0001209191-18-051580-index.htm
2018-12-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118061046/0001209191-18-061046-index.htm
2018-12-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118061049/0001209191-18-061049-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118061051/0001209191-18-061051-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919118061058/0001209191-18-061058-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119006608/0001209191-19-006608-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119006609/0001209191-19-006609-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119006610/0001209191-19-006610-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119006611/0001209191-19-006611-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119006613/0001209191-19-006613-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119018293/0001209191-19-018293-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119018294/0001209191-19-018294-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119019068/0001209191-19-019068-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119021003/0001209191-19-021003-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119021005/0001209191-19-021005-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119021007/0001209191-19-021007-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119021008/0001209191-19-021008-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119021009/0001209191-19-021009-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119039293/0001209191-19-039293-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119039294/0001209191-19-039294-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119039295/0001209191-19-039295-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119039296/0001209191-19-039296-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119039301/0001209191-19-039301-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119049672/0001209191-19-049672-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/0001209191-19-049681-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119049684/0001209191-19-049684-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119049685/0001209191-19-049685-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119049694/0001209191-19-049694-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119050922/0001209191-19-050922-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119050923/0001209191-19-050923-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119051327/0001209191-19-051327-index.htm
2019-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119052479/0001209191-19-052479-index.htm
2019-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119052480/0001209191-19-052480-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/0001209191-19-061574-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119061576/0001209191-19-061576-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919119061579/0001209191-19-061579-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120002030/0001209191-20-002030-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120002034/0001209191-20-002034-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120002038/0001209191-20-002038-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120005704/0001209191-20-005704-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120005705/0001209191-20-005705-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120008463/0001209191-20-008463-index.htm
2020-03-234/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020744/0001209191-20-020744-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020747/0001209191-20-020747-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020751/0001209191-20-020751-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020753/0001209191-20-020753-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020754/0001209191-20-020754-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020755/0001209191-20-020755-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120020756/0001209191-20-020756-index.htm
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120039024/0001209191-20-039024-index.htm
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000120919120039025/0001209191-20-039025-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000149315219002117/0001493152-19-002117-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000149315220002530/0001493152-20-002530-index.htm
2020-02-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1610618/000149315220002833/0001493152-20-002833-index.htm
2019-09-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000156761919018258/0001567619-19-018258-index.htm
2018-08-0910-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061818000087/0001610618-18-000087-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000088/0001610618-18-000088-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061818000089/0001610618-18-000089-index.htm
2018-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000092/0001610618-18-000092-index.htm
2018-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000095/0001610618-18-000095-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000109/0001610618-18-000109-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061818000110/0001610618-18-000110-index.htm
2018-11-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000111/0001610618-18-000111-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061818000118/0001610618-18-000118-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000010/0001610618-19-000010-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1610618/000161061819000012/0001610618-19-000012-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000016/0001610618-19-000016-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000022/0001610618-19-000022-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000024/0001610618-19-000024-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000033/0001610618-19-000033-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061819000035/0001610618-19-000035-index.htm
2019-05-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000036/0001610618-19-000036-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000040/0001610618-19-000040-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000043/0001610618-19-000043-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000050/0001610618-19-000050-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061819000051/0001610618-19-000051-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000055/0001610618-19-000055-index.htm
2019-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000060/0001610618-19-000060-index.htm
2019-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000062/0001610618-19-000062-index.htm
2019-09-058-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000065/0001610618-19-000065-index.htm
2019-09-13DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000067/0001610618-19-000067-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000076/0001610618-19-000076-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061819000078/0001610618-19-000078-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061819000081/0001610618-19-000081-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000004/0001610618-20-000004-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000010/0001610618-20-000010-index.htm
2020-03-0410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1610618/000161061820000011/0001610618-20-000011-index.htm
2020-03-04S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000012/0001610618-20-000012-index.htm
2020-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000014/0001610618-20-000014-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000018/0001610618-20-000018-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000025/0001610618-20-000025-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000026/0001610618-20-000026-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000034/0001610618-20-000034-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061820000035/0001610618-20-000035-index.htm
2020-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000037/0001610618-20-000037-index.htm
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000040/0001610618-20-000040-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000049/0001610618-20-000049-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061820000050/0001610618-20-000050-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1610618/000161061820000057/0001610618-20-000057-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1610618/000161061820000058/0001610618-20-000058-index.htm
2018-11-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1610618/999999999518002907/9999999995-18-002907-index.htm
2020-06-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1610618/999999999520001447/9999999995-20-001447-index.htm

Cidara Therapeutics, Inc (CDTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cidara Therapeutics, Inc (CDTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1754%
Institutional Ownership: 6531%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-09-24James E. LevineChief Financial OfficerBuy30,000.001.9157,240.00205,000.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119050922/0001209191-19-050922-index.htm
2019-09-24Jeffrey SteinPresident & CEOBuy52,500.001.91100,101.75225,619.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119050923/0001209191-19-050923-index.htm
2019-09-12Jeffrey SteinPresident & CEOBuy10,000.00282,320.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049694/0001209191-19-049694-index.htm
2019-03-08Neil AbdollahianChief Business OfficerSell2,300.002.445,612.0030,472.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119018294/0001209191-19-018294-index.htm
2019-01-31Neil AbdollahianChief Business OfficerBuy6,000.0032,772.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119006613/0001209191-19-006613-index.htm
2019-03-07Paul DaruwalaChief Operating OfficerSell2,240.002.555,713.5749,567.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119018293/0001209191-19-018293-index.htm
2019-10-01Neil AbdollahianChief Business OfficerSell7,284.001.9814,422.3249,588.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119052479/0001209191-19-052479-index.htm
2019-01-31Taylor SandisonChief Medical OfficerBuy6,000.0050,722.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119006611/0001209191-19-006611-index.htm
2020-01-03Neil AbdollahianChief Business OfficerSell2,340.003.428,002.8051,248.00https://www.sec.gov/Archives/edgar/data/1610618/000120919120002034/0001209191-20-002034-index.htm
2019-01-31Paul DaruwalaChief Operating OfficerBuy6,000.0051,807.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119006608/0001209191-19-006608-index.htm
2019-09-12Neil AbdollahianChief Business OfficerBuy17,500.0051,972.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/0001209191-19-049681-index.htm
2020-01-03Paul DaruwalaChief Operating OfficerSell2,340.003.428,002.8053,532.00https://www.sec.gov/Archives/edgar/data/1610618/000120919120002030/0001209191-20-002030-index.htm
2019-10-02Paul DaruwalaChief Operating OfficerSell3,295.001.886,194.6055,872.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119052480/0001209191-19-052480-index.htm
2019-09-12Neil AbdollahianChief Business OfficerBuy4,900.0056,872.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/0001209191-19-049681-index.htm
2019-09-12Paul DaruwalaChief Operating OfficerBuy7,500.0057,067.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049672/0001209191-19-049672-index.htm
2019-09-12Taylor SandisonChief Medical OfficerBuy2,500.0057,222.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049685/0001209191-19-049685-index.htm
2019-09-12Taylor SandisonChief Medical OfficerBuy1,400.0058,622.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049685/0001209191-19-049685-index.htm
2019-09-12Paul DaruwalaChief Operating OfficerBuy2,100.0059,167.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049672/0001209191-19-049672-index.htm
2019-01-31Jessica OienGeneral Counsel & SecretaryBuy6,000.006,000.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119006609/0001209191-19-006609-index.htm
2020-03-19James E. LevineChief Financial OfficerBuy25,000.0061,891.00https://www.sec.gov/Archives/edgar/data/1610618/000120919120020747/0001209191-20-020747-index.htm
2020-01-02Jessica OienGeneral Counsel & SecretarySell834.003.863,219.246,965.00https://www.sec.gov/Archives/edgar/data/1610618/000120919120002038/0001209191-20-002038-index.htm
2019-09-27Jessica OienGeneral Counsel & SecretarySell1,001.001.861,861.867,799.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119051327/0001209191-19-051327-index.htm
2019-09-12Jessica OienGeneral Counsel & SecretaryBuy2,800.008,800.00https://www.sec.gov/Archives/edgar/data/1610618/000120919119049684/0001209191-19-049684-index.htm